{{Drugbox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 426291380
| IUPAC_name = [(1''R'',2''R'',5''R'')-2-[2,6-Dimethoxy-4-(2-methyloctan-2-yl)phenyl]-7,7-dimethyl-4-bicyclo[3.1.1]hept-3-enyl]methanol
| image = HU-308.png
| width = 200

<!--Clinical data-->
| tradename =  
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = <!-- A / B            / C / D / X -->
| pregnancy_category =  
| legal_AU = <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 -->
| legal_CA = Schedule II
| legal_UK = <!-- GSL         / P       / POM / CD / Class A, B, C -->
| legal_US = <!-- OTC                   / Rx-only  / Schedule I, II, III, IV, V -->
| legal_status = 
| routes_of_administration =

<!--Pharmacokinetic data-->
| bioavailability =  
| protein_bound =  
| metabolism =  
| elimination_half-life =  
| excretion =

<!--Identifiers-->
| CAS_number_Ref = {{cascite|changed|CAS}}
| CAS_number = 1220887-84-2
| UNII_Ref = {{fdacite|changed|FDA}}
| UNII = 8I5L034D55 
| ATC_prefix =  
| ATC_suffix =  
| PubChem = 5311172
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank =  
| ChemSpiderID      = 8020425
<!--Chemical data-->
| C=27 | H=43 | O=3 
| molecular_weight = 415.63 g/mol
| smiles            = CCCCCCC(C)(C)C1=CC(=C(C(=C1)OC)[C@H]2C=C([C@@H]3C[C@H]2C3(C)C)CO)OC
| StdInChI          = 1S/C27H42O3/c1-8-9-10-11-12-26(2,3)19-14-23(29-6)25(24(15-19)30-7)20-13-18(17-28)21-16-22(20)27(21,4)5/h13-15,20-22,28H,8-12,16-17H2,1-7H3/t20-,21-,22+/m0/s1
| StdInChIKey       = CFMRIVODIXTERW-FDFHNCONSA-N
}}

'''HU-308''' is a drug that acts as a [[cannabinoid]] [[agonist]]. It is highly selective for the [[cannabinoid receptor 2|CB<sub>2</sub>]] [[Receptor (biochemistry)|receptor]] subtype, with a selectivity of over 5000x for CB<sub>2</sub> vs CB<sub>1</sub>.<ref>{{Cite journal |pmid= 10588688 |title= HU-308: a specific agonist for CB(2), a peripheral cannabinoid receptor |issue= 25 |pages= 14228–14233 |pmc= 24419 |doi= 10.1073/pnas.96.25.14228 |journal= Proceedings of the National Academy of Sciences of the United States of America |volume= 96 |author= Hanus, L.|year= 1999 |bibcode= 1999PNAS...9614228H |display-authors=etal}}
</ref> The [[chemical synthesis|synthesis]] and characterization took place in the laboratory of Prof. [[Raphael Mechoulam|Mechoulam]] at the [[Hebrew University of Jerusalem]] in the late 1990s. It has [[analgesic]] effects,<ref>{{Cite journal
| last1 = Labuda | first1 = C.
| last2 = Koblish | first2 = M.
| last3 = Little | first3 = P.
| title = Cannabinoid CB2 receptor agonist activity in the hindpaw incision model of postoperative pain
| journal = European Journal of Pharmacology
| volume = 527
| issue = 1–3
| pages = 172–174
| year = 2005
| pmid = 16316653
| doi = 10.1016/j.ejphar.2005.10.020
}}</ref> promotes [[cell proliferation|proliferation]] of [[neural stem cells]],<ref>{{Cite journal |author= Palazuelos, J.|title= Non-psychoactive CB2 cannabinoid agonists stimulate neural progenitor proliferation |journal= The FASEB Journal |volume= 20 |issue= 13 |pages= 2405–2407 |year= 2006 |pmid= 17015409 |doi= 10.1096/fj.06-6164fje |display-authors=etal}}
</ref> and protects both liver and blood vessel tissues against [[oxidative stress]] via inhibition of [[TNF-α]].<ref>{{Cite journal
| author= Rajesh | first= M.
| last2= Pan | first2= H.
| last3= Mukhopadhyay | first3= P.
| last4= Batkai | first4= S.
| last5= Osei-Hyiaman | first5= D.
| last6= Hasko | first6= G.
| last7= Liaudet | first7= L.
| last8= Gao | first8= B.
| last9= Pacher | first9= P. |title= Pivotal Advance: Cannabinoid-2 receptor agonist HU-308 protects against hepatic ischemia/reperfusion injury by attenuating oxidative stress, inflammatory response, and apoptosis |journal= Journal of leukocyte biology |volume= 82 |issue= 6 |pages= 1382–1389 |year= 2007 |pmid= 17652447 |doi= 10.1189/jlb.0307180 |pmc= 2225476 }}
</ref><ref>{{Cite journal |author= Rajesh, M.|title= CB2-receptor stimulation attenuates TNF-α-induced human endothelial cell activation, transendothelial migration of monocytes, and monocyte-endothelial adhesion |journal=American Journal of Physiology. Heart and Circulatory Physiology |volume= 293 |issue= 4 |pages= H2210–H2218 |year= 2007 |pmid= 17660390 |doi= 10.1152/ajpheart.00688.2007 |pmc= 2229632 |display-authors=etal}}
</ref>

==Legal status==

===United States===
HU-308 is not scheduled at the federal level in the [[United States]].<ref name="PART 1308 — SCHEDULES OF CONTROLLED SUBSTANCES - 1308.11 Schedule I">[http://www.deadiversion.usdoj.gov/21cfr/cfr/1308/1308_11.htm 21 CFR — SCHEDULES OF CONTROLLED SUBSTANCES §1308.11 Schedule I.]</ref>

====Florida====
"HU-308 ([(1''R'',2''R'',5''R'')-2-[2,6-dimethoxy-4-(2-methyloctan-2-yl)phenyl]-7,7-dimethyl-4-bicyclo[3.1.1]hept-3-enyl]methanol)" is a Schedule I [[controlled substance]] in the state of [[Florida]] making it illegal to buy, sell, or possess in Florida.<ref name="Florida Statutes - Chapter 893 - DRUG ABUSE PREVENTION AND CONTROL">[http://leg.state.fl.us/statutes/index.cfm?App_mode=Display_Statute&URL=0800-0899/0893/0893.html Florida Statutes - Chapter 893 - DRUG ABUSE PREVENTION AND CONTROL]</ref>

==See also==
* [[HU-210]]
* [[HU-320]]

==References==
{{reflist}}
{{Cannabinoids}}

[[Category:Cannabinoids]]
[[Category:Alcohols]]
[[Category:Phenol ethers]]
[[Category:HU cannabinoids]]
[[Category:Designer drugs]]
[[Category:CB2 receptor agonists]]


{{cannabinoid-stub}}